Myelodysplastic syndromes (MDS) are hematopoietic disorders characterized by peripheral cytopenias and risk of progression to leukemia. MDS patients (pts) are often anemic, resulting in increased red blood cell transfusions (tfns) and fatigue. Previous studies have shown that 150mcg/week (wk) or 300mcg/wk of the erythropoiesis-stimulating agent (ESA) darbepoetin alfa (DA) can raise hemoglobin (Hb) levels in low-risk MDS pts (

Patton et al. J Support Oncol. 2005;3:419–426
). We present data from a phase 2, single-arm, open-label study on the efficacy of 500mcg DA administered every three wks (Q3W) for treating anemia in low-risk MDS pts. Eligibility criteria included ≥18 years, anemia (Hb ≤11g/dL), and low- or intermediate-1-risk MDS (IPSS definition). If pts did not respond by wk 7, the dosing frequency was escalated to Q2W. After the last DA dose on wk 52, the end of study (EOS) was wk 53 (Q2W dosing) or wk 55 (Q3W dosing). The primary endpoint was the percentage of pts with an erythroid response (International Working Group criteria) by wk 13. Secondary 53/55-wk endpoints included incidence of erythroid responses, incidence of tfns, and the change in Hb levels and FACT-F score from baseline (BL). Results were stratified by whether pts had prior ESA therapy: ESA-naive (ESA-N) vs prior ESA-treated (ESA-T). A previous interim analysis showed that low-risk MDS pts could achieve an erythroid response after 13 wks of DA 500mcg Q3W (
Gabrilove et al. Blood. 2005;106:abstract2541
). This is the first reported summary after 53/55 wks (n=148). Of 98 ESA-N pts, 47% were men, 85% were white, and the mean (SD) age was 74 (10) years; the 50 ESA-T pts had similar demographics. Both ESA-N and ESA-T pts had similar BL Hb (Table). By wk 53/55, the percentage (95% CL) of pts with a major erythroid response (≥2g/dL Hb rise from BL or tfn independence) was 56% (46, 66) in ESA-N pts and 30% (17, 43) in ESA-T pts. Both ESA-N and ESA-T pts had a clinically meaningful rise (≥3 points) in FACT-F score from BL. Of the 148 pts, 89% reported adverse events (AEs) with the most common AE being fatigue, 7% had AEs considered related to DA treatment, and 1.4% had thromboembolic events. These results suggested that DA 500mcg Q3W was well tolerated and increased Hb levels in the MDS pts in this study.

ESA-N, N=98ESA-T, N=50
KM%= Kaplan-Meier percentage 
Crude % (95% CL) pts with a major erythroid response 56% (46, 66) 30% (17, 43) 
Crude % (95% CL) pts with a minor erythroid response 15% (8, 22) 20% (9, 31) 
Mean (SD) BL Hb, g/dL 9.8 (1.0) [n=84] 10.0 (1.2) [n=41] 
Mean (SD) Hb change (BL to wk 53/55) (last value carried forward) 1.1 (1.6) [n=84] 0.2 (1.7) [n=41] 
Crude % (95% CL) pts achieved target Hb (11g/dL) 68% (58, 78) [n=87] 46% (31, 60) [n=46] 
Mean (SD) Hb after reached Hb target, g/dL 11.7 (0.8) [n=68] 11.6 (0.9) [n=25] 
KM% (95% CL) pts with tfns (wk 1 to EOS) 29% (19, 39) 43% (27, 59) 
KM% (95% CL) pts with tfns (wk 5 to EOS) 28% (19, 38) [n=96] 43% (26, 60) [n=45] 
Mean (SD) change in FACT-F score (BL to wk 53/55) 5.8 (8.6) [n=45] 7.2 (9.3) [n=15] 
ESA-N, N=98ESA-T, N=50
KM%= Kaplan-Meier percentage 
Crude % (95% CL) pts with a major erythroid response 56% (46, 66) 30% (17, 43) 
Crude % (95% CL) pts with a minor erythroid response 15% (8, 22) 20% (9, 31) 
Mean (SD) BL Hb, g/dL 9.8 (1.0) [n=84] 10.0 (1.2) [n=41] 
Mean (SD) Hb change (BL to wk 53/55) (last value carried forward) 1.1 (1.6) [n=84] 0.2 (1.7) [n=41] 
Crude % (95% CL) pts achieved target Hb (11g/dL) 68% (58, 78) [n=87] 46% (31, 60) [n=46] 
Mean (SD) Hb after reached Hb target, g/dL 11.7 (0.8) [n=68] 11.6 (0.9) [n=25] 
KM% (95% CL) pts with tfns (wk 1 to EOS) 29% (19, 39) 43% (27, 59) 
KM% (95% CL) pts with tfns (wk 5 to EOS) 28% (19, 38) [n=96] 43% (26, 60) [n=45] 
Mean (SD) change in FACT-F score (BL to wk 53/55) 5.8 (8.6) [n=45] 7.2 (9.3) [n=15] 
View Large

Topics:
anemia, darbepoetin alfa, myelodysplastic syndrome, brachial plexus neuritis, fatigue, adverse event, cytopenia, erythrocyte transfusion, erythropoiesis-stimulating agents, hemoglobin

Disclosures: Darbepoetin alfa is not FDA-approved for treating anemia in MDS patients. Since anemia commonly develops in patients with MDS, it is of interest to examine if the erythropoiesis-stimulating agent darbpoetin alfa can correct anemia in this patient population.; Dr. Lam: employee of Amgen Inc.; Dr. Dreiling: employee of Amgen Inc.; Dr. Lyons: consultant to Amgen for thrombocytopenia and myelodysplasia (payment less than $5,000); Dr. Gabrilove: Ad hoc consultant to Hoffman LaRoche, Fibrogen, and Celgene; Dr. Mushtaq: Consultant to Amgen about MDS.; Dr. Lam: ownership of Amgen stock options; Dr. Dreiling: ownership of Amgen stock.; Amgen provided funding for this MDS study in which Dr. Gabrilove, Dr. Paquette, Dr. Lyons, Dr. Mushtaq, and Dr. Sekeres were investigators; Dr. Sekeres: received research funding from Celgene; Dr. Gabrilove: support for clinical research studies from Amgen and Fibrogen.; Dr. Paquette: honoraria from speaking at Amgen-sponsored meetings and educational activities; Dr. Sekeres: honoraria from Celgene, Pharmion, and Telik; Dr. Mushtaq: honoraria from Amgen for presentation of MDS study; Dr. Gabrilove: honoraria from Amgen and Celgene.; Dr. Sekeres: Celgene and Pharmion; Dr. Lyons: Amgen advisory board for this MDS study; Dr. Gabrilove: On speakers bureau and ad hoc advisory boards for Amgen, Hoffman LaRoche, Celgene, and Fibrogen.

Author notes

*

Corresponding author

2006, The American Society of Hematology
2006
Sign in via your Institution